Ikarian Capital’s Viridian Therapeutics VRDN Stock Holding History

Ikarian Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-175,100	Closed	-$3.36M	–	221
2024 Q4	$3.36M	Sell	175,100 -24,900	-12%	-$541K	0.46%	61
2024 Q3	$4.55M	Buy	200,000 +199,000	+19,900%	+$3.25M	0.63%	48
2024 Q2	$1.3M	Buy	+1,000	New	+$13.8K	0.23%	64
2022 Q3	–	Sell	-300,000	Closed	-$3.47M	–	159
2022 Q2	$3.47M	Buy	+300,000	New	+$4.03M	0.63%	46

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ikarian Capital's VRDN Position: Q2 2026 in Review

Ikarian Capital opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 425,000 shares worth $7.81M. The stake represents 0.84% of the portfolio and ranks #34 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in VRDN as recently as Q3 2025.

Ikarian Capital first reported a position in VRDN in Q3 2024 and has held it in 6 quarters since. The position peaked at $11.4M in Q3 2024. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Ikarian Capital held 425,000 shares of Viridian Therapeutics worth $7.81M as of Q2 2026.
Viridian Therapeutics was a new Ikarian Capital position in Q2 2026.
Viridian Therapeutics made up 0.84% of Ikarian Capital's portfolio in Q2 2026, its #34 holding.
Ikarian Capital first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 6 quarters since.
Ikarian Capital's Viridian Therapeutics position peaked at $11.4M in Q3 2024.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.